

# MODELE EUROPEEN DE CURRICULUM VITAE

## INFORMATIONS PERSONNELLES

Name **LAMARTINA LIVIA**  
Telephone 0033 1 4211 3321  
e-mail Livia.LAMARTINA@gustaveroussy.fr  
Number of Inscription to professional French medical council 20824 (Répertoire Partagé des Professionnels de Santé 10101801628)  
Current position **Practitioner/specialist, Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France**

## EDUCATION AND TRAINING

2019-2020 **Higher learning course “Molecular Medicine in Oncology”, Ecole de Sciences du Cancer**  
2015 - 2019 **PhD “Biomedical Technologies In Clinical Medicine”, University of Rome “Sapienza”**  
2017 - 2018 **Higher learning course “Pedagogy and medical teaching”, University of Rome “Sapienza”**  
2010 - 2015 **Specialist in Internal Medicine, University of Rome “Sapienza”**  
2003 - 2009 **Degree in Medicine and Surgery, University of Rome “Sapienza”**  
1998 - 2003 **Classical studies diploma, “N. Spedalieri” High school, Catania**

## WORK EXPERIENCE

May 2010 – May 2015 Resident in Internal Medicine  
Name and address of employer Prof. Sebastiano Filetti, Department of Translational and Precision Medicine, Policlinico Umberto I, viale del Policlinico 155, 00161 Roma, Italia  
02/05/2012 – 31/10/2013 Resident in Internal Medicine  
Name and address of employer Prof. M. Schlumberger, Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif

## CLINICAL TRIALS

Principal Investigator in :

- RIFTOS MKI - Radioactive Iodine refractory asymptomatic patients in differentiated Thyroid cancer » Study number: 17852
- “European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib (CAPRELSA™) 300 mg in RET Mutation Negative and RET Mutation Positive Patients with Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer (MTC)”, protocol number D4200C00104

Co-investigator in the following clinical trials:

“A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)”

“An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer (XL 184-301)”

“A multi-center Expanded Access Program for compassionate use of lenvatinib in the treatment of Radioiodine-Refractory Differentiated Thyroid Cancer”

“A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)” - E7080-M000-213

“A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer” – XL184-40

“Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RAS or BRAFV600E mutation” – MERAIODE

“A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy” - COSMIC

“A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients” – EXAMINER

## RESEARCH ACTIVITY

**Coordination** of the Italian Thyroid Cancer Observatory from 2013 to 2018.

**Collaboration** in the national French network TUTHYREF

**Coordination** and organization of the following research projects in collaboration with authoritative Italian and foreign institutions (*Institut Jules Bordet Comprehensive Cancer Center, Brussels, Belgium; Johns Hopkins University, Baltimore, USA*):

1. Thyroid cancer incidence in children and adolescents (French project: 22/11/2020- 18/01/2021)
2. Follow-up of low risk thyroid cancer patients: can we stop follow-up after 5 years of complete remission? (International project: 10/07/2019-10/04/2020)
3. Locally unresectable differentiated thyroid cancer: outcomes and perspectives (French project: 15/05/2019- 10/03/2019)
4. An update on the management of low risk differentiated thyroid cancer. (French project: 15/03/2019- 01/09/2019)
6. Screening for differentiated thyroid cancer in selected populations (International project: 15/06/2018- 04/10/2019)
7. Follow-up of differentiated thyroid cancer - what should (and what should not) be done. (International project: 22/10/2017- 01/08/2018)
8. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). (Italian project: 06/02/2017 – 30/11/2017)
9. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. (International project: 22/11/2016 – 5/10/2017)
10. Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory. (Italian Project: 01/03/2016 – 10/11/2017)
11. Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors. (International project: 02/09/2012 – 01/03/2017)
12. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. (Italian project: 23/04/2015 - 14/12/2015)
13. ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. (International project: 08/09/2015 - 01/06/2016)
14. Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer. (International project: 14/04/2015 - 17/05/2016)
15. Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer. (International project: 02/05/2013 - 15/04/2016)
16. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. (International project: 29/01/2014 – 13/01/2015)
17. Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the "con" point of view. (International project: 25/08/2014 - 10/01/2015)

## PEER REVIEW

Peer review activity for the following journals: Endocrine ; European Journal of Endocrinology; International Journal of Endocrinology ; Lancet Diabetes and Endocrinology ; Ultrasound International Open; Journal of Clinical Medicine

## BIBLIOMETRIC INDEX

H-index: 20 (Scopus) ; N. of publications : 47 (Scopus)

## MOTHER TONGUE

ITALIAN

## OTHER LANGUAGES

ENGLISH

FRENCH

## SCIENTIFIC SOCIETIES

European Thyroid Association and Endocrine Society since 2016

## PUBLICATIONS

1. **LAMARTINA L**, Leboulleux S, Schlumberger M. Thyroid cancer incidence in children and adolescents. *Lancet Diabetes Endocrinol*. 2021 Jan 19:S2213-8587(20)30430-7. doi: 10.1016/S2213-8587(20)30430-7. Online ahead of print.
2. Grani G **LAMARTINA L**, Alfo M, Ramundo V, Falcone R, Giacomelli L, Biffoni M, Filetti S, Durante C. Selective use of radioactive iodine therapy for papillary thyroid cancers with low or lower-intermediate recurrence risk. *J Clin Endocrinol Metab*. 2020 Dec 30:dga973. doi: 10.1210/clinem/dgaa973. Online ahead of print.
3. Sparano C, Godbert Y, Attard M, Do Cao C, Zerdoud S, Roudaut N, Joly C, Berdelou A, Hadoux J, **LAMARTINA L**, Schlumberger M, Leboulleux S. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. *Endocr Relat Cancer* 2021 Jan;28(1):15-26. doi: 10.1530/ERC-20-0106.
4. Hartl DM, Bidault S, Girard E, Guerlain J, Breuskin I, **LAMARTINA L**, Terroir M, Leboulleux S. Ultrasound visualization of the vagus nerve for intraoperative neuromonitoring in thyroid surgery *Eur Radiol* 2020 Nov 25. doi: 10.1007/s00330-020-07472-7.
5. Hartl DM, Guerlain J, Breuskin I, Hadoux J, Baudin E, Al Ghuzlan A, Terroir-Cassou-Mounat M, **LAMARTINA L**, Leboulleux S. Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer. *Cancers (Basel)* 2020 Nov 6;12(11):3282. doi: 10.3390/cancers12113282.
6. Rubino M, Scoazec JY, Pisa E, Faron M, Spaggiari L, Hadoux J, Spada F, Planchard D, Cella CA, Leboulleux S, De Marinis F, Ducreux M, **LAMARTINA L**, Baudin E, Fazio N. Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. *Lung Cancer* 2020 Oct;148:149-158. doi: 10.1016/j.lungcan.2020.08.001.
7. Ramundo V, Di Gioia CRT, Falcone R, **LAMARTINA L**, Biffoni M, Giacomelli L, Filetti S, Durante C, Grani G. Diagnostic Performance of Neck Ultrasonography in the Preoperative Evaluation for Extrathyroidal Extension of Suspicious Thyroid Nodules. *World J Surg* 2020 Aug;44(8):2669-2674. doi: 10.1007/s00268-020-05482-6.
8. **LAMARTINA L**, Handkiewicz-Junak D. Follow-up of low risk thyroid cancer patients: can we stop follow-up after 5 years of complete remission? *Eur J Endocrinol*. 2020 May;182(5):D1-D16. doi: 10.1530/EJE-19-0960.
9. **LAMARTINA L**, Godbert Y, Nascimento C, Do Cao C, Hescot S, Borget I, Al Ghuzlan A, Hartl D, Hadoux J, Pottier E, Attard M, Berdelou A, Terroir M, Baudin E, Schlumberger M, Leboulleux S; with the support of the TUTHYREF network. Locally unresectable differentiated thyroid cancer: outcomes and perspectives *Endocrine [Epub ahead of print]* DOI 10.1007/s12020-020-02245-0
10. **LAMARTINA L**, Grani G, Durante C, Filetti S, Cooper DS. Screening for differentiated thyroid cancer in selected populations. *Lancet Diabetes Endocrinol*. 2019 Oct 4. [Epub ahead of print] Review.
11. **LAMARTINA L**, Leboulleux S, Terroir M, Hartl D, Schlumberger M. An update on the management of low risk differentiated thyroid cancer. *Endocr Relat Cancer*. 2019 Sep 1 [Epub ahead of print] Review.
12. Hartl DM, Hadoux J, Guerlain J, Breuskin I, Haroun F, Bidault S, Leboulleux S, **LAMARTINA L**. Risk-oriented concept of treatment for intrathyroid papillary thyroid cancer. *Best Pract Res Clin Endocrinol Metab*. 2019 Jun 4:101281.[Epub ahead of print] Review.
13. Grani G, Ramundo V, Falcone R, **LAMARTINA L**, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Verrienti A, Schlumberger M, Filetti S, Durante C. Thyroid Cancer Patients With No Evidence of Disease: The Need for Repeat Neck Ultrasound. *J Clin Endocrinol Metab*. 2019 Nov 1;104(11):4981-4989.
14. **LAMARTINA L**, Montesano T, Falcone R, Biffoni M, Grani G, Maranghi M, Ciotti L, Giacomelli L, Ramundo V, Lomonaco C, Di Gioia CR, Lucia P, Ronga G, Durante C. Is it worth suppressing TSH in low- and intermediate-risk papillary thyroid cancer patients before the first disease assessment? *Endocr Pract*. 2018 Nov 1.
15. Grani G, **LAMARTINA L**, Ascoli V, Bosco D, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, Durante C. Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: towards the "right" TIRADS. *J Clin Endocrinol Metab*. 2019 Jan 1;104(1):95-102.
16. Grani G, **LAMARTINA L**, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, Durante C. Sonographically estimated risks of malignancy for thyroid nodules computed with five standard classification systems: changes over time and their relation to malignancy. *Thyroid*. 2018 Sep;28(9):1190-1197.
17. **LAMARTINA L**, Grani G, Durante C, Borget I, Filetti S, Schlumberger M. Follow-up of differentiated thyroid cancer - what should (and what should not) be done. *Nat Rev Endocrinol*. 2018 Sep;14(9):538-551.
18. Durante C, Grani G, **LAMARTINA L**, Filetti S, Mandel SJ, Cooper DS. The Diagnosis and Management of Thyroid Nodules: A Review. *JAMA*. 2018 Mar 6;319(9):914-924
19. Berdelou A, **LAMARTINA L**, Klain M, Leboulleux S, Schlumberger M; TUTHYREF Network. Treatment of refractory thyroid cancer. *Endocr Relat Cancer*. 2018 Apr;25(4):R209-R223.

20. **LAMARTINA L**, Grani G, Durante C, Filetti S. Recent advances in managing differentiated thyroid cancer. *F1000 Faculty Rev.* 18 Jan 2018,
21. Grani G, **LAMARTINA L**, Cantisani V, Maranghi M, Lucia P, Durante C. Interobserver agreement of various thyroid imaging reporting and data systems. *Endocr Connect.* 2018 Jan;7(1):1-7.
22. **LAMARTINA L**, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, Bellantone R, Pontecorvi A, Montesano T, Pagano L, Daniele L, Fugazzola L, Ceresini G, Bruno R, Rossetto R, Tumino S, Centanni M, Meringolo D, Castagna MG, Salvatore D, Nicolucci A, Lucisano G, Filetti S, Durante C. 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect *Endocr Relat Cancer.* 2018 Mar;25(3):L7-L11.
23. Grani G\*, **LAMARTINA L\***, Durante C, Filetti S, Cooper DS. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. *Lancet Diabetes Endocrinol.* 2018 Jun;6(6):500-514. \***Equal contribution.**
24. **LAMARTINA L**, Durante C, Lucisano G, Grani G, Bellantone R, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, Antonelli A, Limone P, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Spiazzi G, Mian C, Persani L, Barbaro D, Nicolucci A, Filetti S. Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory. *Thyroid.* 2017 Dec;27(12):1490-1497.
25. **LAMARTINA L**, Borget I, Mirghani H, Al Ghuzlan A, Berdelou A, Bidault F, Deandreis D, Baudin E, Travagli JP, Schlumberger M, Hartl DM, Leboulleux S. Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors. *J Clin Endocrinol Metab.* 2017 Mar 1;102(3):1020-1031.
26. Rosignolo F, Sponziello M, Giacomelli L, Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, **LAMARTINA L**, Grani G, Durante C, Filetti S, Verrienti A. Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up. *J Endocr Soc.* 2017 Jan 12;1(1):3-13.
27. Grani G, **LAMARTINA L**, Ascoli V, Bosco D, Nardi F, D'Ambrosio F, Rubini A, Giacomelli L, Biffoni M, Filetti S, Durante C, Cantisani V. Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules. *Endocrine.* 2017 Aug;57(2):256-261.
28. **LAMARTINA L**, Deandreis D, Durante C, Filetti S. ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. 2016 Nov;175(5):R185-202.
29. **LAMARTINA L**, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K, Sponziello M, Trulli F, Verrienti A, Filetti S, Durante C. Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer. *J Clin Endocrinol Metab.* 2016 Aug;101(8):3036-44.
30. **LAMARTINA L**, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, Al Ghuzlan A, Hartl D, Blanchard P, Terroir M, Deandreis D, Schlumberger M, Baudin E, Leboulleux S. Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer. *J Clin Endocrinol Metab.* 2016 Jul;101(7):2733-41.
31. **LAMARTINA L**, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, Durante C. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. *Endocrine.* 2016 Nov;54(2):467-475. doi:10.1007/s12020-015-0823-3
32. Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M, **LAMARTINA L**, Nicolucci A, Filetti S. (2015). The Natural History of Benign Thyroid Nodules. *JAMA.* 2015 Mar 3;313(9):926-35.
33. **LAMARTINA L**, Durante C, Filetti S, Cooper DS (2015). Low and intermediate Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A systematic review of the literature. *J Clin Endocrinol Metab.* 2015 May;100(5):1748-61

**DATE** 02/03/2021

**SIGNATURE** LIVIA LAMARTINA

